Minimal residual disease (MRD)—minute populations of cancer cells undetectable by conventional imaging—remains the chief ...
FDA approves daratumumab for high-risk smoldering multiple myeloma, transforming treatment strategies and enhancing patient ...
Ike Onwere, MD: It is [sometimes] based on giving the FOLFOX [leucovorin, fluorouracil, and oxaliplatin] every 2 weeks. It’s ...
Biomarkers such as ring sideroblasts are indicators for response to treatments like luspatercept (Reblozyl). In patients with ...
Comprehensive biomarker testing is central to the management of metastatic non-small cell lung cancer (NSCLC). Widespread ...
Sonrotoclax (BGB-11417), an investigational, next-generation BCL2 inhibitor, has received priority review designation from the FDA for the treatment of adult patients with relapsed or refractory (R/R) ...
Lifileucel showed a 31.4% objective response rate and a median duration of response of 36.5 months in advanced melanoma patients. The median overall survival was 13.9 months, with adverse events ...
The subcutaneous formulation of toripalimab demonstrated noninferior pharmacokinetics compared to the intravenous version in treating nonsquamous NSCLC. The study confirmed comparable efficacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback